Explore more publications!
Djibouti Health Journal
Submit Press Release

Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 2, 2025

Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States
September 2, 2025

Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States

Indeterminate GlobeNewswire
Alterity Therapeutics to Present at the Biotech Showcase
September 2, 2025

Alterity Therapeutics to Present at the Biotech Showcase

Indeterminate GlobeNewswire
Kraig Biocraft Laboratories' Lead Sericulture Expert Joins Recombinant Spider Silk Production Team at New Rearing Facility in Southeast Asia
September 2, 2025

Kraig Biocraft Laboratories' Lead Sericulture Expert Joins Recombinant Spider Silk Production Team at New Rearing Facility in Southeast Asia

Indeterminate GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 2, 2025

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Indeterminate GlobeNewswire
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
September 2, 2025

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Indeterminate GlobeNewswire
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 2, 2025

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Indeterminate GlobeNewswire
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
September 2, 2025

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

Indeterminate GlobeNewswire
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 2, 2025

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Indeterminate GlobeNewswire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Indeterminate GlobeNewswire
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
September 2, 2025

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Indeterminate GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in September
September 2, 2025

Neumora Therapeutics to Participate in Upcoming Conferences in September

Indeterminate GlobeNewswire
Seer Appoints Isaac Ro to its Board of Directors
September 2, 2025

Seer Appoints Isaac Ro to its Board of Directors

Indeterminate GlobeNewswire
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
September 2, 2025

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Indeterminate GlobeNewswire
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
September 2, 2025

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Indeterminate GlobeNewswire
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
September 2, 2025

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Indeterminate GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2025

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
September 2, 2025

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Indeterminate GlobeNewswire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
September 2, 2025

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Indeterminate GlobeNewswire
AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases
September 2, 2025

AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases

Indeterminate GlobeNewswire
Kamada to Participate in Upcoming September Investor Conferences
September 2, 2025

Kamada to Participate in Upcoming September Investor Conferences

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions